Autoimmune hepatitis natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
| Line 23: | Line 23: | ||
===Prognosis=== | ===Prognosis=== | ||
*Prognosis is generally excellent, and the 10-year survival rate of patients with Autoimmune hepatitis treated with immunosuppressive therapy is approximately 80%.<ref name="pmid21396370">{{cite journal |vauthors=Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, Gleeson D |title=Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center |journal=Gastroenterology |volume=140 |issue=7 |pages=1980–9 |year=2011 |pmid=21396370 |doi=10.1053/j.gastro.2011.02.065 |url=}}</ref><ref name="pmid16298014">{{cite journal |vauthors=D'Amico G, Garcia-Tsao G, Pagliaro L |title=Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies |journal=J. Hepatol. |volume=44 |issue=1 |pages=217–31 |year=2006 |pmid=16298014 |doi=10.1016/j.jhep.2005.10.013 |url=}}</ref> | *Prognosis is generally excellent, and the 10-year survival rate of patients with Autoimmune hepatitis treated with immunosuppressive therapy is approximately 80%.<ref name="pmid21396370">{{cite journal |vauthors=Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, Gleeson D |title=Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center |journal=Gastroenterology |volume=140 |issue=7 |pages=1980–9 |year=2011 |pmid=21396370 |doi=10.1053/j.gastro.2011.02.065 |url=}}</ref><ref name="pmid16298014">{{cite journal |vauthors=D'Amico G, Garcia-Tsao G, Pagliaro L |title=Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies |journal=J. Hepatol. |volume=44 |issue=1 |pages=217–31 |year=2006 |pmid=16298014 |doi=10.1016/j.jhep.2005.10.013 |url=}}</ref> | ||
*Prognosis is | *Prognosis is bad without treatment, 50% of patients with severe autoimmune hepatitis will die in a 5 years, and 80-90% of patients will die within 10 years of disease onset. | ||
*Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent. | *Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent. | ||
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy]. | *The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy]. | ||
Revision as of 02:00, 28 December 2017
|
Autoimmune hepatitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Autoimmune hepatitis natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Autoimmune hepatitis natural history, complications and prognosis |
|
FDA on Autoimmune hepatitis natural history, complications and prognosis |
|
CDC on Autoimmune hepatitis natural history, complications and prognosis |
|
Autoimmune hepatitis natural history, complications and prognosis in the news |
|
Blogs on Autoimmune hepatitis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: :Manpreet Kaur, MD [2]
Overview
Natural History
- The symptoms of Autoimmune hepatitis usually has a bimodal age distribution, with a first peak of incidence at age 10-20 years and a second at age 45-70 years in the second decade of life, and start with asymptomatic to .[1]
- If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Complications
Common complications of Autoimmune hepatitis include:[2][3]
- Cirrhosis and complications of cirrhosis:
- Portal hypertension
- Esophageal varices
- Metabolic bone disease
- Hyperlipidaemia
- Hypovitaminosis of cholestasis
- Pruritis of cholestasis
Prognosis
- Prognosis is generally excellent, and the 10-year survival rate of patients with Autoimmune hepatitis treated with immunosuppressive therapy is approximately 80%.[4][5]
- Prognosis is bad without treatment, 50% of patients with severe autoimmune hepatitis will die in a 5 years, and 80-90% of patients will die within 10 years of disease onset.
- Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
- The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis
References
- ↑ Sonthalia N, Rathi PM, Jain SS, Surude RG, Mohite AR, Pawar SV, Contractor Q (2017). "Natural History and Treatment Outcomes of Severe Autoimmune Hepatitis". J. Clin. Gastroenterol. 51 (6): 548–556. doi:10.1097/MCG.0000000000000805. PMID 28272079.
- ↑ Trivedi PJ, Hirschfield GM (2013). "Treatment of autoimmune liver disease: current and future therapeutic options". Ther Adv Chronic Dis. 4 (3): 119–41. doi:10.1177/2040622313478646. PMC 3629750. PMID 23634279.
- ↑ Gleeson D, Heneghan MA (2011). "British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis". Gut. 60 (12): 1611–29. doi:10.1136/gut.2010.235259. PMID 21757447.
- ↑ Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, Gleeson D (2011). "Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center". Gastroenterology. 140 (7): 1980–9. doi:10.1053/j.gastro.2011.02.065. PMID 21396370.
- ↑ D'Amico G, Garcia-Tsao G, Pagliaro L (2006). "Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies". J. Hepatol. 44 (1): 217–31. doi:10.1016/j.jhep.2005.10.013. PMID 16298014.